What We Know About Donald Trump’s COVID-19 Treatment Plan

The President was hospitalized on Friday evening and has been receiving an aggressive treatment of experimental and standard drugs.

Written byLisa Winter

| 3 min read

Save for Later

Listen with Speechify

0:00

3:00

ABOVE: © ISTOCK.COM, WELLESENTERPRISES

On Thursday, October 1, it was announced that President Donald Trump, First Lady Melania Trump, and other White House officials had tested positive for SARS-CoV-2. His symptoms worsened and on Friday evening, he was admitted to Walter Reed National Military Medical Center in Bethesda, Maryland.

There has been some mixed messaging with the actual timeline of when he received his diagnosis and began a treatment regimen, as The New York Times reports, and doctors can only speculate on his prognosis.

Here is what is currently known about the drugs Trump has been taking to combat his illness:

One of the first reported treatments Trump received was an experimental cocktail of two monoclonal antibodies from Regeneron. Trump was intravenously given eight grams of the cocktail, which is the highest dose used during the drug’s small, 245-person clinical trial. According to a September press release from Regeneron, the ...

Interested in reading more?

The Scientist ARCHIVES

Become a Member of

Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!

Join for free today

Already a member?

Add The Scientist as a preferred Google source to see more of our trusted coverage.

Meet the Author

Lisa Winter
Go to The Scientist's LinkedIn Page
Lisa joined The Scientist in 2017. As social media editor, some of her duties include creating content, managing interactions, and developing strategies for the brand’s social media presence. She also contributes to the News & Opinion section of the website. Lisa holds a degree in Biological Sciences with a concentration in genetics, cell, and developmental biology from Arizona State University and has worked in science communication since 2012.
View Full Profile